Ikarian Capital, LLC Sage Therapeutics, Inc. Call Options Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 13, 2022	BUY	$30.71 - $45.71 $7.54 Million - $11.2 Million	245,500 Added 5455.56%	250,000 $8.28 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $166,770 - $211,995	4,500 New	4,500 $192,000
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $10.2 Million - $14.6 Million	-254,300 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $8.23 Million - $11.9 Million	150,000 Added 143.82%	254,300 $14.4 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $1.6 Million - $2.19 Million	22,600 Added 27.66%	104,300 $7.81 Million
Q4 2020 Feb 12, 2021	BUY	$58.41 - $89.06 $140,184 - $213,744	2,400 Added 3.03%	81,700 $7.07 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $6.17 Million - $9.37 Million	-150,000 Reduced 65.42%	79,300 $4.85 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $1.95 Million - $3.24 Million	75,000 Added 48.61%	229,300 $9.53 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $4.03 Million - $11.9 Million	154,300 New	154,300 $4.43 Million

218

46.4M

847K

188K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.